Shanghai Ennova Biopharmaceutical Co. Ltd. has identified condensed ring compounds acting as ATP-dependent 6-phosphofructokinase, liver type (PFKL) activators reported to be useful for the treatment of cancer, autoimmune disease, inflammatory disorders, lung diseases, metabolic diseases, sepsis and thrombosis.

Ennovabio (Zhejiang) Pharmaceuticals Co. Ltd. and Shanghai Ennova Biopharmaceutical Co. Ltd. have described 5-membered and 6-membered heterocyclic compounds acting as non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of cancer, viral infection, transplant rejection, cardiovascular and inflammatory disorders, and autoimmune, myeloproliferative and metabolic diseases.

Mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors, reported to be potentially useful for the treatment of cancer, have been detailed in a patent from Ennovabio (Zhejiang) Pharmaceuticals Co. Ltd. and Shanghai Ennova Biopharmaceutical Co. Ltd.